menu
    • menu
    [{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"AGT100216","moa":"HDAC6","graph1":"Neurology","graph2":"Preclinical","graph3":"Augustine Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Augustine Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Augustine Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AGT-100216","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Augustine Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Augustine Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Augustine Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"AGT-100216","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Augustine Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Augustine Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Augustine Therapeutics \/ Novo Holdings"}]

    Find Clinical Drug Pipeline Developments & Deals by Augustine Therapeutics

    Menu

    Augustine Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Augustine Therapeutics

                            Belgium arrow
                            AAPS
                            Not Confirmed

                            Augustine Therapeutics

                            Belgium arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGT-100216

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Augustine Announces first patient Dosed in Ph1 Trial evaluating lead candidate AGT-100216

                            Details : AGT-100216 is the first peripherally-restricted, selective HDAC6 inhibito. It is being evaluated for the treatment of Charcot-Marie-Tooth disease

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 27, 2025

                            Lead Product(s) : AGT-100216

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Augustine Therapeutics

                            Belgium arrow
                            AAPS
                            Not Confirmed

                            Augustine Therapeutics

                            Belgium arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGT-100216

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Novo Holdings

                            Deal Size : $84.8 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Augustine Raises EUR 78M/USD 85M in Oversubscribed Series A Financing

                            Details : The financing will support the company's lead product AGT-100216, which is being evaluated for the treatment of Charcot-Marie-Tooth.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 24, 2025

                            Lead Product(s) : AGT-100216

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Novo Holdings

                            Deal Size : $84.8 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Augustine Therapeutics

                            Belgium arrow
                            AAPS
                            Not Confirmed

                            Augustine Therapeutics

                            Belgium arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGT100216

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $18.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Augustine Therapeutics Raises €17 Million in Series A for Neurological Lead Candidate

                            Details : The proceeds from the financing will be used to advance Augustine’s lead candidate, AGT100216, into early-stage clinical trials for the treatment of CMT and CIPN.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 26, 2024

                            Lead Product(s) : AGT100216

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $18.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth